Skip to content


    Exciting News for WebMD Members!

    We've been busy behind the scenes building new message boards for you. You'll have new and easier ways to find messages, connect with others, and share your stories.

    And, this will all be available on your smartphone or other mobile device!

    What Do You Need to Do?

    The message board you're used to will be closing in the coming weeks. While many of your boards will be making the move to our new home, your posts will not. Want to keep a discussion going? Save posts you want to continue (this includes your member profile story), so that you can re-post them in the new message boards.

    Keep an eye here and on your email inbox, we'll be back in touch soon to give you all the information you need!

    Yours in health,
    WebMD Message Boards Management

    Statins and Inclusion Body Myositis
    iride6606 responded:
    Interesting article and he could be right but I have a few issues. First off, he discusses an increase in cases over 50. How much of an increase? The incidence rate for this disease is 1 in 51.3 million in people over 50, that's almost incalculable. Even if it has doubled or tripled in the period of statins, that would be 2 cases per year based on the number of prescriptions out there. I find it hard to believe that this person knows that many people with Inclusion Body Myositis, the numbers don't hunt. Secondly, the symptoms of Inclusion Body Myositis don't usually start until after 50 so his subset is moot.

    Even if this guy is right, it can almost certainly never be proved just by the rarity of the condition. In a randomized trial you would need every person taking a statin involved to find a results.

    Interesting in any case.
    billh99 replied to iride6606's response:
    On report indicates a rate of sIBM of 16 to 70 (at different times & countries) per million for people over 50.

    But I don't know if what is reported in statin users is the same. They both have autoimmune responses. I don't understand all of the terms, but I saw a couple of things that make me think that they might be different.

    Statins & Immune-Mediated Necrotizing Myopathy There are numerous case reports and small series that suggest that statins may be associated with idiopathic inflammatory myopathies in the traditional sense — dermatomyositis (DM), and polymyositis (PM), for example.[a title="Link: undefined">[5> There has been no conclusive proof of causality, and often the temporal relationship between the commencement of the statin and the development of DM or PM is the main reason a link between the two is suspected. In recent years, however, there has been mounting evidence pointing to an immune-mediated necrotizing myopathy associated with statin use that persists even in spite of statin withdrawal. Needham and colleagues were the first to report these findings.[a title="Link: undefined">[6> They investigated muscle pathology of eight patients with persistent myopathy despite statin withdrawal. All had myofiber necrosis. Only three had an inflammatory infiltrate, but MHC-I was upregulated. Following this case series,

    New research suggests that statins appear to upregulate the expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA), the major target of autoantibodies in patients who develop statin-associated autoimmune necrotizing myopathy. The results, according to investigators, provide a mechanistic link between an environmental trigger, statin therapy, and the development of a sustained autoimmune disorder that persists even after the drugs have been stopped. "In the vast majority of cases, in patients who develop muscle symptoms while taking statins, the symptoms resolve once you have the patient stop taking the statin, without any needed form of treatment," lead investigator Dr Andrew Mammen (Johns Hopkins Medical Institute, Baltimore, MD) told heartwire . "But there is a rare group of patients who develop a sustained autoimmune process that actually requires immunosuppressive therapy to treat. Otherwise, they continue to get worse and worse, with many of our patients coming into the clinic in wheelchairs, even after having been off the statin for months."
    Their findings are published in the December 2010 issue of Arthritis & Rheumatism.

    Approximately 5% of individuals prescribed statins develop some sort of muscle side effects, such as cramping or muscle pain, that can lead to switching to another drug or stopping the medication altogether. Mammen stressed that the response resulting in necrotizing myopathy is extremely rare, doing a back-of-envelope calculation suggesting that one or two individuals per million per year develop the autoimmune disorder.

    iride6606 replied to billh99's response:
    Even at 16 per million, do the math. The number of proven cases, if any, would be so small it would be insignificant even if the incidence rate doubled, which no proof has been provided to show us. Remember the word in the title, "postulate" which means to guess or have a hunch. There should be more research, he may be right but no one is going to fund such a huge study for such minor results. As you can read, the author has no intention to. The paper I quoted above showed a rate of 51.3 per million for over 50s which was the highest incidence rate I could find. I quoted it incorrectly as 1 in 51.3 million, I meant 53.1 per 1 million, but again, do the math and you'll see it would be very difficult to get a significant result.

    Featuring Experts

    There are no Expert stories for this community right now

    Helpful Tips

    Statin use is generally safe, and NOT associated with cancer and myopathy
    This network meta-analysis study provides evidence on the comparative tolerability and harms of individual statins. Overall, statins as a ... More
    Was this Helpful?
    1 of 2 found this helpful

    Related Drug Reviews

    • Drug Name User Reviews

    Report Problems With Your Medications to the FDA

    FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.